AATec Medical GmbH | WebDisclosure

Switch to English

8295	Sociétés
114831	Mots-clés
55272	Articles
62429	Communiqués

Accueil
Sociétés
AATec Medical GmbH

BRÈVE

publiée le 18/09/2024 à 10:05, il y a 2 mois 3 jours

AATec Medical Welcomes Professor James Chalmers to Scientific Advisory Board

Scientific Advisory Board AATec Medical James Chalmers Bronchiectasis Recombinant AAT
BRÈVE

publiée le 18/09/2024 à 10:05, il y a 2 mois 3 jours

AATec Medical accueille le professeur James Chalmers au sein de son conseil consultatif scientifique

AATec Medical Conseil Consultatif Scientifique James Chalmers Bronchectasie AAT Recombinante
COMMUNIQUÉ DE PRESSE

publié le 18/09/2024 à 10:00, il y a 2 mois 3 jours

AATec Medical Welcomes Professor James Chalmers to Scientific Advisory Board
AATec Medical welcomes Professor James Chalmers, a renowned expert in respiratory medicine, to its Scientific Advisory Board to advance product development in non-CF bronchiectasis

Scientific Advisory Board AATec Medical Professor James Chalmers Respiratory Medicine Non-CF Bronchiectasis
BRÈVE

publiée le 24/07/2024 à 10:05, il y a 3 mois 28 jours

AATec Medical Makes Significant Strides in First Year of Operations

Biotechnology Clinical Trials AATec Medical ATL-105 Inflammatory Lung Diseases
BRÈVE

publiée le 24/07/2024 à 10:05, il y a 3 mois 28 jours

AATec Medical réalise des progrès significatifs au cours de sa première année d'exploitation

Biotechnologie AATec Medical ATL-105 Essais Cliniques Maladies Pulmonaires Inflammatoires
COMMUNIQUÉ DE PRESSE

publié le 24/07/2024 à 10:00, il y a 3 mois 28 jours

AATec Medical reports significant progress in company’s first year towards unlocking the therapeutic potential of AAT
AATec Medical reports significant progress in unlocking therapeutic potential of AAT for treating inflammatory lung diseases in its first year. Company advances lead candidate ATL-105 for NCFB

AATec Medical ATL-105 Inflammatory Lung Diseases Therapeutic Potential NCFB
BRÈVE

publiée le 29/02/2024 à 09:30, il y a 8 mois 21 jours

AATec Medical enrichit son Conseil Scientifique avec l'arrivée du Professeur Claus Franz Vogelmeier

AATec Medical Professeur Claus Franz Vogelmeier Maladies Inflammatoires Pulmonaires Conseil Scientifique Alpha-1 Antitrypsine
BRÈVE

publiée le 29/02/2024 à 09:30, il y a 8 mois 21 jours

AATec Medical enriches its Scientific Council with the arrival of Professor Claus Franz Vogelmeier

AATec Medical Professor Claus Franz Vogelmeier Inflammatory Lung Diseases Scientific Council Alpha-1 Antitrypsin
COMMUNIQUÉ DE PRESSE

publié le 29/02/2024 à 09:30, il y a 8 mois 21 jours

AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board
AATec Medical appoints Prof. Dr. Claus Franz Vogelmeier, a renowned pulmonology expert, to its Scientific Advisory Board, enhancing expertise in inflammatory lung diseases. Visit www.aatec-medical.com for details

Scientific Advisory Board AATec Medical Inflammatory Lung Diseases Alpha-1 Antitrypsin Professor Dr. Claus Franz Vogelmeier
COMMUNIQUÉ DE PRESSE

publié le 06/02/2024 à 09:00, il y a 9 mois 15 jours

AATec Medical starts collaboration with the German Federal Agency for Disruptive Innovation SPRIND for alpha-1 antitrypsin
AATec Medical collaborates with German Federal Agency for Disruptive Innovation SPRIND to develop ATL-105, a recombinant alpha-1 antitrypsin platform for respiratory diseases, including viral infections and inflammatory diseases

Respiratory Diseases AATec Medical German Federal Agency For Disruptive Innovation SPRIND ATL-105 Recombinant Alpha-1 Antitrypsin

Les Echos

Publié le 21/11/2024 à 06:58, il y a 3 heures 32 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 3 heures 32 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 3 heures 32 minutes

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 14 heures 23 minutes

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 15 heures 10 minutes

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 21/11/2024 à 10:03, il y a 27 minutes

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Publié le 21/11/2024 à 10:00, il y a 30 minutes

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Publié le 21/11/2024 à 09:00, il y a 1 heure 30 minutes

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Publié le 21/11/2024 à 00:35, il y a 9 heures 55 minutes

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Publié le 21/11/2024 à 00:25, il y a 10 heures 5 minutes

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

Voir tout ACCESSWIRE

EQS Group

Publié le 21/11/2024 à 10:04, il y a 25 minutes

Supervisory Board appoints Carsten Schmitt as new CFO
Publié le 21/11/2024 à 10:02, il y a 28 minutes

Supervisory Board appoints Carsten Schmitt as new CFO
Publié le 21/11/2024 à 10:00, il y a 30 minutes

Nabaltec AG continues solid earnings performance in third quarter of 2024
Publié le 21/11/2024 à 10:00, il y a 30 minutes

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Publié le 21/11/2024 à 09:41, il y a 49 minutes

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy